EVARREST Fibrin Sealant Patch, developed by Ethicon, a part of Johnson & Johnson, received FDA clearance. The patch was designed to be used to help control bleeding during adult liver surgeries. It contains human thrombin and fibrinogen proteins that participate in clot formation and is bio absorbable.
The EVARREST patch had a nearly double improvement in ability to stop bleeding in difficult to control bleeding regions. It retains its strength and stickiness while it's still around, and eases the difficulty while handling liver surgery.
"The liver is a particularly hard-to-control bleed site during surgery, as blood loss is often higher and hemostasis may be difficult to achieve," said Krishna Athota, M.D, trauma and critical care surgeon at the University of Cincinnati College of Medicine.
Clinical studies demonstrate that EVARREST is greater than 94% effective compared to current standard of care in controlling bleeding across challenging patient types and surgical situations.
"This expanded indication for EVARREST reinforces this innovation's potential to make problematic bleeding situations routine, and could result in a paradigm shift in the treatment of bleeding during surgery," he added.